Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
AssigneeIPS Heart
InventorMuhammad Ashraf
Life of this patent
Estimating the term…
Abstract
This disclosure provides a chemically modified induced pluripotent stem (iPS) cell derived from parental cells and methods for generating the chemically induced pluripotent stem (iPS) cells, as well as cardiac progenitor cells capable of producing cells of multiple sub-lineages. The iPS cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue or to rejuvenating cardiac muscles in a patient in need thereof and to treat cardiac disease.
Claims12
A method of repairing cardiac tissue, said method comprising:
- culturing induced pluripotent stem cells (iPSCs) or pluripotent stem cells (PSCs) in a medium without insulin and with isoxazole or isoxazole-9 in an amount effective to induce differentiation for 3-7 days and then culturing in said medium with insulin and without said isoxazole or isoxazole-9 for 7-10 days to produce cardiac progenitor cells or cardiomyocytes;
- and
- injecting said cardiac progenitor cells or cardiomyocytes, or progeny thereof, into damaged cardiac tissue of a heart of a human patient in an amount sufficient for cardiac tissue repair.
A method of preparing cells for repair of cardiac tissue, said method comprising:
- culturing induced pluripotent stem cells (iPSCs) or pluripotent stem cells (PSCs) in a medium without insulin and with isoxazole or isoxazole-9 in an amount effective to induce differentiation for 3-7 days and then culturing in said medium with insulin and without said isoxazole or isoxazole-9 for 7-10 days to produce cardiac progenitor cells or cardiomyocytes.
A population of cardiac progenitor cells or cardiomyocytes, characterized by:
- i) overexpression of Nkx-2.5 and one or more cardiac markers selected from ISL1, GATA4, ΔMHC, sarcomeric actin, Gαi, mir-133 mir-762 CCL7, CXCR2, CXC5, integral membrane protein 2A, and ephrin A3,
- ii) underexpression of one or more pluripotency markers selected from a miR-290-295 cluster, let-7 family, Dnmt1, Dnmt3b, and Max, and
- iii) underexpression of one or more DNA methyltransferase genes, each as compared with untreated iPSCs or PSCs.
Dependencies are inferred from the claim text.